Drew Ranieri
Stock Analyst at Morgan Stanley
(1.28)
# 3,274
Out of 4,829 analysts
164
Total ratings
44.94%
Success rate
-12.47%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $2.99 | +101.01% | 4 | Mar 5, 2025 | |
| GMED Globus Medical | Upgrades: Overweight | $83 → $100 | $59.01 | +69.46% | 12 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $388.08 | +14.67% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $18.77 | +1.25% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $13.67 | +97.51% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $7.19 | +11.27% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $23.66 | -7.02% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $13.37 | -40.16% | 13 | Jul 15, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $16 | $12.67 | +26.28% | 8 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $16.29 | +406.45% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $18.56 | +104.74% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $70.26 | +36.64% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $13.10 | +98.47% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $175.34 | +68.24% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $129.24 | +116.65% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $6.74 | -25.82% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $31.88 | +119.57% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $561.43 | -46.57% | 6 | Apr 25, 2022 |
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $2.99
Upside: +101.01%
Globus Medical
Dec 2, 2024
Upgrades: Overweight
Price Target: $83 → $100
Current: $59.01
Upside: +69.46%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $388.08
Upside: +14.67%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $18.77
Upside: +1.25%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $13.67
Upside: +97.51%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $7.19
Upside: +11.27%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $23.66
Upside: -7.02%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $13.37
Upside: -40.16%
Alphatec Holdings
Jul 15, 2024
Maintains: Overweight
Price Target: $19 → $16
Current: $12.67
Upside: +26.28%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $16.29
Upside: +406.45%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $18.56
Upside: +104.74%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $70.26
Upside: +36.64%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $13.10
Upside: +98.47%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $175.34
Upside: +68.24%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $129.24
Upside: +116.65%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $6.74
Upside: -25.82%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $31.88
Upside: +119.57%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $561.43
Upside: -46.57%